skip to Main Content

Season 3, Episode 16 - Liver Cancer in 2022: Wrap-up & Outlook

Results from current clinical trials are rapidly evolving, with mixed results. In this EASL Studio the faculty will be discussing:

  • why certain trials have failed whereas others have succeeded,
  • what we have learned about the connection between overall survival and progression-free survival as endpoints, and
  • how the systemic therapy of HCC has evolved.

Faculty: Prof. Tom Lüdde (Moderator), Prof. Peter Galle (Moderator), Prof. Bruno Sangro (Faculty), Dr Anna Saborowski (Faculty)

Related episodes

ℹ The episode will be broadcasted live on this page.

Add event to calendar

Apple Google Office 365 Outlook Outlook.com Yahoo

Back To Top